Frontiers | Nine Things Genomics Can Tell Us About Candida auris
Candida auris: MDR Fungus Among Us
Antifungal Resistance Trends of Candida auris Clinical Isolates in New York and New Jersey from 2016 to 2020 | Antimicrobial Agents and Chemotherapy
JoF | Free Full-Text | Immunopathogenesis of Emerging Candida auris and Candida haemulonii Strains
Increasing prevalence, molecular characterization and antifungal drug susceptibility of serial Candida auris isolates in Kuwait | PLOS ONE
Microorganisms | Free Full-Text | Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum
Candida auris: A systematic review and meta‐analysis of current updates on an emerging multidrug‐resistant pathogen - Osei Sekyere - 2018 - MicrobiologyOpen - Wiley Online Library
Identification and antifungal drug susceptibility pattern of Candida auris in India Deshkar S, Patil N, Amberkar S, Lad A, Siddiqui F, Sharan S - J Global Infect Dis
How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST) - ScienceDirect
JoF | Free Full-Text | International Multicentre Study of Candida auris Infections
Frontiers | Nine Things Genomics Can Tell Us About Candida auris
Comparison between CDC-suggested tentative MIC breakpoints and... | Download Scientific Diagram
Clinical, microbiological, and genomic characteristics of clade-III Candida auris colonization and infection in southern California, 2019–2022 | Infection Control & Hospital Epidemiology | Cambridge Core
Modulation of key antioxidant enzymes and cell cycle arrest as a possible antifungal mode of action of cinnamaldehyde based azole derivative - ScienceDirect
Clinical, microbiological, and genomic characteristics of clade-III Candida auris colonization and infection in southern California, 2019–2022 | Infection Control & Hospital Epidemiology | Cambridge Core
Antifungal Resistance Trends of Candida auris Clinical Isolates in New York and New Jersey from 2016 to 2020 | Antimicrobial Agents and Chemotherapy
Clinical breakpoints and epidemiologic cutoff values for Candida... | Download Scientific Diagram
Candida auris: Diagnostic Challenges and Emerging Opportunities for the Clinical Microbiology Laboratory | SpringerLink
MIC50, MIC90, MIC range and geometric mean of five antifungal agents... | Download Scientific Diagram
Candida auris: MDR Fungus Among Us
Triazole antifungal MIC of C. auris clinical isolates and derivative... | Download Scientific Diagram
xmlinkhub
How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST) - Clinical Microbiology and Infection
Frontiers | Review on Antifungal Resistance Mechanisms in the Emerging Pathogen Candida auris
Frontiers | Silver Nanoantibiotics Display Strong Antifungal Activity Against the Emergent Multidrug-Resistant Yeast Candida auris Under Both Planktonic and Biofilm Growing Conditions
C. auris strains were collected from Montefiore Medical Center (MMC)... | Download Scientific Diagram
Candida auris: A systematic review and meta‐analysis of current updates on an emerging multidrug‐resistant pathogen - Osei Sekyere - 2018 - MicrobiologyOpen - Wiley Online Library
In vivo emergence of high-level resistance during treatment reveals the first identified mechanism of amphotericin B resistance in Candida auris | bioRxiv
![PDF] First reported case of multidrug-resistant Candida auris in Canada. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/ae0bea639831fb9878b2b64c7718e62901286483/2-Table1-1.png "PDF] First reported case of multidrug-resistant Candida auris in Canada. | Semantic Scholar")